Table 2.
Treatment Modalities of COVID-19 Patients in ICU.
| Treatment modalities (n = 470) | |
|---|---|
| Standard treatment for COVID-19 | |
| Favipiravir, n (%) | 345 (73.4) |
| Hydroxychloroquine and Favipiravir, n (%) | 56 (11.9) |
| Hydroxychloroquine, Favipiravir, Azithromycin and Oseltamivir, n (%) | 55 (11.7) |
| Hydroxychloroquine, Favipiravir and Azithromycin, n (%) | 5 (1.1) |
| Hydroxychloroquine, Azithromycin and Oseltamivir, n (%) | 4 (0.9) |
| Additional treatment modalities | |
| Remdesivir, n (%) | 21 (4.5) |
| Intravenous immunoglobulin, n (%) | 14 (3.0) |
| Convalescent plasma therapy, n (%) | 64 (13.6) |
| Stem-cell therapy, n (%) | 2 (0.4) |
| Anti-inflammatory treatment | |
| Dexamethasone, n (%) | 182 (38.7) |
| Pulse of 1 g of methylprednisolone, n (%) | 71 (15.1) |
| Pulse of 250 mg of methylprednisolone, n (%) | 149 (31.7) |
| Tocilizumab, n (%) | 155 (33.0) |
| Extracorporeal membrane oxygenation therapy, n (%) | 9 (1.9) |
| Continuous renal replacement therapy, n (%) | 150 (31.9) |